


# IMPACT OF IMMUNOSSUPRESSION WITHDRAWAL IN DONOR(HLA)SPECIFIC MEMORY B CELL RESPONSES IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS

**Alba Torija<sup>1</sup>,** Delphine Kervella<sup>1</sup>, Laura Donadeu<sup>1</sup>, Maria Meneghini<sup>1</sup>, Elena Crespo<sup>1</sup>, Rico Buchli<sup>2</sup>, Alberto Sanchez-Fueyo<sup>3</sup>, John Bucuvalas<sup>4</sup>, Sandy Feng<sup>5</sup>, Oriol Bestard<sup>1</sup>

<sup>1</sup> Vall d'Hebron Research Institute, Vall d'Hebron University Hospita, <sup>2</sup> Pure Protein, LLC, <sup>3</sup> King's College London, <sup>4</sup> Mount Sinai Hospital, <sup>5</sup> University of California San Francisco

# **BACKGROUND**


#### **Compartmentalized biology of humoral memory**




# **BACKGROUND**

#### Monitoring circulating HLA-sp mBCs in organ transplantation

# Detection of HLA-sp mBCs in highly sensitized kidney transplant patients



# Donor(HLA)-sp mBCs precede subsequent Abmediated graft lesions




Luque S et al Am J Transplant 2018


Lúcia, Marc, et al. Kidney international 88.4 (2015)

# **BACKGROUND**

#### Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients (iWITH, NCT01638559)



→ determine, among stable long-term pediatric liver transplant recipients, the efficacy and safety of immunosuppression withdrawal to identify operational tolerance.



#### **Study groups**

Presence of DSA			Rejection	
DSA baseline	No DSA baseline		Tolerant	Non-tolerant
	De novo DSA	None		

# **HYPOTHESIS**

# Describe donor(HLA)-reactive mBCs prior to and during IS withdrawal in pediatric liver transplant recipients




- Identify donor(HLA)-specific mBCs in pediatric liver transplant recipients with DSA at baseline
- Monitor donor(HLA)-specific mBC responses during IS withdrawal
- Track donor(HLA)-specific mBCs at time of rejection

# Methdology

1948 activity


#### Assessment of HLA-specific ASCs by ELISPOT or fluorospot assay

1997 activity



5 spots 3 spots HLA-sp IgG activity = (Sum of Spot sizes multiplied on Spot intensities)/1000


#### Detection of donor(HLA)-sp mBCs before IS withdrawal





Patients with circulating anti-HLA antibodies show higher numers of circulating HLA-sp mBCs


#### **Evolution of donor(HLA)-sp mBCs during IS withdrawal**





Donor(HLA)-sp mBCs increase during IS withdrawal in all patients and significantly in those with no DSA at baseline


Donor(HLA)-sp mBCs in patients with de novo DSA appearance during IS withdrawal



#### Donor(HLA)-sp mBCs and allograft tolerance

# Donor(HLA)-sp lgG-producing BCS activity/ 450.000 cells TOL non-TOL Baseline During IS withdrawal

#### Donor(HLA)-sp mBCs at time of rejection



No differences in donor(HLA)-sp mBCs were observed between tolerant and non-tolerant recipients

Donor(HLA)-sp mBCs increase at time of rejection in patients without DSA at baseline

# Conclusions

- HLA-sp mBCs can be detected circulating in pediatric liver transplant recipients with positive DSAs.
- Those HLA-sp mBCs seem to appear over time and increase its frequencies during IS withdrawal.
- HLA-sp mBCs can be detected in prior to DSA appearance.
- HLA-sp mBCs frequencies increase at time of rejection and seem to play an active role in humoral immune activation

# **ACKNOWLEDGEMENTS**

#### Vall d'Hebron Research Institute:

- Alba Torija

- Mariona Juvé
- Delphine Kervella
- Núria Bolaños
- Laura Donadeu
- Cristina Font

- Elena Crespo

#### Vall d'Hebron University Hospital:

- Oriol Bestard

- Francesc Moreso
- Maria Meneghini

#### **University of California San Francisco**

- Sandy Feng

#### **King's College London**

Alberto Sanchez-Fueyo





